Introduction: Low awareness of Alzheimer's disease (AD) clinical trials is a recruitment barrier. To assess whether online education may affect screening rates for AD prevention clinical trials, we conducted an initial prospective cohort study (n = 10,450) and subsequent randomized study (n = 351) using an online digital tool: AlzU.org.
INTRODUCTION
Rapid and cost-effective recruitment for clinical trials is fraught with challenges. Nearly two billion dollars is spent annually in the United States on patient recruitment, and most clinical trials require timeline extensions due to recruitment difficulties. 1 These significant challenges also exist in the field of Alzheimer's disease (AD), as it is estimated that over 500,000 volunteers need to be screened to enroll 70,000 participants for >150 planned or ongoing clinical trials. 2 Due to ineffective or inefficient recruitment practices, investigators face increased costs and fail to meet study deadlines, which ultimately delays the regulatory approval of new therapeutics. 1, 3, 4 In addition, insufficient recruitment results in missed opportunities for patients who may benefit from the interventions administered in these clinical trials. Identifying strategies that improve recruitment would, therefore, benefit trialists, clinical researchers, and patients. 5 Potential barriers to efficient recruitment include a general lack of public awareness about clinical trials 6, 7 and recruitment methods that have not kept pace with advances in communications and other technologies. 3 Therefore, online educational strategies that are free, widely promoted, and available to the general public may facilitate recruitment in a rapid and cost-effective manner. 7, 8 Alzheimer's Universe (www.AlzU.org) is a free online digital tool and educational portal with evidence-based resources for people at risk for AD; it was created to educate the public about AD clinical trials and risk-reduction strategies. 9 The conceptual framework aims to educate users about AD in order to influence awareness, beliefs, willingness, and intentions to ultimately drive behavioral change. 10 In a prior randomized study, participation in AlzU.org significantly improved users' knowledge about AD, as well as several measures of behavioral intent such as willingness to participate in an AD prevention clinical trial. 9 However, it was unclear whether self-reported measures of increased interest would translate into real-world behavioral change of screening and enrolling in an AD prevention clinical trial.
In this article, we present two sequential studies investigating the impact of AlzU.org on screening and enrollment into the "Anti-Amyloid Treatment in Asymptomatic Alzheimer's disease" (A4) AD prevention trial. 11 We first conducted a prospective cohort study to investigate the relationship between AlzU.org lesson completion rates (low, medium, and high "dose") and A4 screening and enrollment. We then conducted a randomized controlled trial (RCT) with new participants to investigate the influence of AlzU.org on A4 screening and enrollment.
METHODS

Overview of AlzU.org
The AlzU.org online digital educational tool has been described previously. 9 The course tested included six lessons ranging from 6 to 16 minutes in length (64 minutes total): (1) introduction to AD, (2) 
Study design and participants
From June 15, 2015 to January 31, 2017, participants were recruited via internet marketing, social media, broadcast media, and other outreach initiatives to join AlzU.org and complete a six-lesson course. 13 Inclusion criteria were willingness to opt-in to longitudinal study survey emails and age 65 to 85. Exclusion criteria were previous screening After the initial prospective cohort study (June 15, 2015 to December 23, 2016), two refinements were made to AlzU.org to improve content accessibility and lesson completion rates/user retention: (1) lessons were updated to be compatible with mobile devices and 
Procedures
Randomization (randomized controlled trial)
Between January 2, 2017 and January 31, 2017, participants who joined AlzU.org were randomized to one of the two courses available.
The intervention group completed a six-lesson interactive web-based course accessible via computer, tablet, and personal mobile devices. 
Outcomes
The primary outcome was rate of screening and enrollment into the A4 clinical trial six months after joining AlzU.org. In the cohort study, screening and enrollment rates were compared across the three lesson groups. In the RCT, screening and enrollment rates were compared between the intervention and control groups in participants who reported AlzU.org as the specific influencing factor for their decision.
Statistical analyses
Prospective cohort analyses
The analyses were pre-specified to compare three "doses" of lesson exposure: group 1 (zero to one lesson completed; 0 to 7 minutes), group 2 (two to four lessons completed; 17 to 45 minutes), and group 3 (five or more lessons completed; 60 to 64 minutes). Analyses were completed using R version 3.5.1. The primary outcome was analyzed using chi-square goodness-of-fit tests to explore differences in A4 screening/enrollment rates among lesson completion groups. Post hoc analyses were conducted to determine if there were significant differences in screening and enrollment rates between specific lesson completion groups.
Randomized-controlled trial analyses
All analyses were pre-specified as intention-to-treat (ITT), but utilized a modified ITT population because those who had already screened or enrolled in the A4 study were excluded from analyses. The primary outcome was analyzed using a Fisher's exact test to assess the influence of AlzU.org on A4 screening/enrollment between intervention and control groups. 
RESULTS
Cohort study
Participants and recruitment
Referral sources
A total of 9379 responses were received from participants (89.75%) regarding referral source to AlzU.org. The largest referral source (n = 2977, 28.49%) was Facebook.com, followed by the Dr. Oz Show (n = 1763, 16.9%), internet site (n = 1565, 14.97%), EndAlzNow.org (n = 892 or 8.53%), and CNN.com (n = 397, 3.80%). The remaining participants were referred through a large variety of other sources (Table 1 ).
Lesson completion rates
A total of 10,224 participants were included in lesson completion analyses at 6 months (n = 226 were excluded due to e-mail bounce back deactivations): 7085 (69.3%) were in group 1 (completed zero to one lesson), 1912 (18.7%) were in group 2 (two to four lessons), and 1227 (12.0%) were in group 3 (five or more lessons). The referral source that led to the highest completion rate was EndAlzNow.org, with 27.7%
completing five or more lessons and 27.5% completing two to four lessons.
Screening and enrollment rates
A total of 2469 participants (23.6%) completed the end-of-study questionnaire assessing the impact of AlzU.org on screening for the A4 clinical trial ("screen rate"): 1153 were in group 1 (46.7%), 623 in group 2 (25.2%), and 693 were in group 3 (28.1%). Forty-five participants in group 1 (screen rate = 3.9%), 31 in group 2 (screen rate = 5.0%), and 58 in group 3 (screen rate = 8.4%) indicated that they had screened for the A4 study ( Figure 2) . A chi-square goodness-of-fit test found differences in screening rates among the groups (P = 0.0002).
Post hoc analyses showed differences in A4 screening rates between groups 1 and group 3 (P < 0.0001), and between groups 2 and 3 (P = 0.0194), with group 3 having higher screening rates in both cases.
Of the 134 participants who reported screening for the A4 clinical trial, 33 reported that they ultimately enrolled: 15 from group 1 (enrollment rate = 1.3%), 7 from group 2 (enrollment rate = 1.1%), and 11 from group 3 (enrollment rate = 1.6%) ( Figure 2) . A chi-square goodness-of-fit test determined that there were no significant differences in enrollment among the groups (P = 0.2335). 
Randomized-controlled trial
Subjects and recruitment
Referral sources
A total of 272 (77.5%) of the 351 participants reported their referral source ( Table 2 ). Facebook.com (n = 77, 21.9%) and endALZnow.org (n = 58, 16.5%) were the most commonly reported referral sources, and this was the case in both groups.
Lesson completion rates
Within the control group, 66 participants completed zero lessons (38.5%), while 105 completed one lesson in addition to varying amounts (0 to 57 minutes) of matched duration video content. Within the intervention group, 58 participants completed zero lessons F I G U R E 2 A4 trial screening and enrollment rates by AlzU.org lesson completion group. Note: There were significant differences in screening between groups 1 and 3 (P < 0.001) and between groups 2 and 3 (P = 0.0194). There were no significant differences in enrollment between groups (32.2%), 11 completed one lesson (6.1%), 38 completed two to four lessons (21.1%), and 73 completed five or more lessons (40.6%).
Screening and enrollment rates
Analyses were performed using a modified ITT analysis. Five participants in the intervention group screened for the A4 clinical trial, compared to none in the control group. Two participants in the intervention group enrolled in the A4 clinical trial, compared to none in the control group. Assumptions were not met for chi-square goodness-of-fit, so Fisher's exact test was used to test the hypothesis that screening rates were equal between the experimental groups.
There was insufficient evidence to reject this hypothesis (P = 0.0611).
As there were no subjects from the control group that screened, no hypothesis test was run on enrollment rates (Figure 3 ).
DISCUSSION
This study demonstrates that AlzU.org, an online digital tool for AD education, may be a worthwhile strategy for improving screening rates for AD prevention clinical trials. The prospective cohort study demonstrated an association between lesson completion rate and A4 trial recruitment, with participants in the highest lesson completion group demonstrating the greatest A4 screening rates. However, no significant differences in enrollment rates were found between the lesson completion groups.
After completion of the cohort study, all online educational content was modified to improve content accessibility and lesson completion rates/user retention by updating lesson content to be compatible with mobile devices and adding additional email reminders if available lessons remained incomplete. The subsequent RCT was planned to similarly enroll 10,000 participants; however, due to the earlier than F I G U R E 3 A4 trial screening and enrollment rates in intervention and control group. Note: We observed a trend in screening between the intervention and control groups (P = 0.061). There was no significant difference in enrollment between the two groups expected closure of recruitment to the A4 trial, participants could only be enrolled for 29 days. Although there were no significant differences in enrollment rates in the RCT, we did observe a trend in screening rates between intervention and control groups (P = 0.0611). One potential reason for the lack of significance was the relatively small sample size (n = 351) when compared against the cohort study (n = 10,450). Further study is warranted in larger populations to draw more definitive conclusions.
AlzU.org is a free online resource that has accumulated a source of potential trial-ready participants who are intrinsically motivated were recruited from online and social media (with the greatest number recruited from Facebook). 13 Our previous studies have similarly found that social media advertising via Facebook led to rapid and costeffective study recruitment, and as such was an effective means of disseminating awareness of clinical trials. 19 Although another prior randomized study demonstrated that AlzU.org can successfully provide knowledge about AD risk reduction and increase subjective willingness to participate in a clinical trial, 9 this study demonstrates the potential of the AlzU.org digital tool to objectively increase screening rates in AD clinical trials in the real-world.
This study has several limitations. One notable limitation is that all participants had access to some educational materials posted on the website, including a Clinical Trials information page and blog.
These resources were available for all participants regardless of lesson ticipants. This may be represented by the higher response rates in questions at baseline in participants who also completed the postsurvey. Therefore, future studies addressing these limitations are needed.
Other limitations include the lack of diversity within the participant pool, as most participants (in both the cohort study and RCT) reported as female and Caucasian. Given that trial recruitment from underrepresented populations has been a well-documented challenge, this is an important limitation that warrants further investigation. Future studies are necessary to evaluate the effectiveness of varied recruitment strategies, including online education, in underrepresented populations.
Despite the limitations presented, this study lends support for further study of the use of online educational interventions to promote screening and enrollment for AD clinical trials. By taking advantage of recent advances in communication practices and technology as a whole, we believe that online interventions can facilitate the recruitment process. 4 Investigating the possible barriers that exist between the public and their willingness to participate in AD education, screening, clinical trials, and risk reduction is essential for the advancement of therapeutic interventions in the field of AD. 14 It is also imperative to consider the effect of recruitment efforts on participant engagement and retention in clinical trials. 20 Therefore, in addition to studying recruitment through AlzU.org, future studies evaluating participant engagement and retention in clinical trials are warranted.
CONCLUSION
Digital tools such as AlzU.org may present a promising framework to promote screening for AD prevention clinical trials. Furthermore, this approach may serve as a potentially reproducible model that may be applied to other areas of clinical research outside of AD prevention. Further study of online educational interventions for clinical trial recruitment is warranted to build upon these findings.
